QTVascular

MEDIA RELEASE

QT VASCULAR ANNOUNCES FDA APPROVAL OF SECOND GENERATION CHOCOLATE® PTCA BALLOON CATHETER

Highlights:

- **Chocolate® PTCA balloon catheter designed to reduce vessel trauma during balloon inflation**
- **Second generation device now features hydrophilic coating**

SINGAPORE, 14 April 2015 – QT Vascular Ltd., together with its subsidiaries ("**QT Vascular**" or the "**Group**"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced Federal Drug Administration's approval of the second generation (Gen 2) of the Chocolate® Percutaneous Transluminal Coronary Angioplasty balloon catheter (Chocolate® PTCA). Chocolate® PTCA is indicated for balloon dilatation of the stenotic portion of coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.

Chocolate® PTCA is a novel device designed to dilate diseased coronary vessels in a less traumatic way compared to conventional balloon angioplasty. It utilizes a unique constraining element on the outside of the balloon that reduces the stress the vessel experiences during inflation and forces the balloon to expand in a uniform manner.

Building from the clinical experience of the first generation of the Chocolate® PTCA (Gen 1) which has been used extensively in both simple and highly complex coronary cases, Gen 2 of Chocolate® PTCA now features a highly lubricious hydrophilic coating on its distal shaft. The addition of this coating is expected to reduce friction and enhance the catheter's movement in highly tortuous lesions.

"Unlike some peripheral vessels, coronary arteries can be extremely tortuous, thus providing a delivery challenge for novel devices. Nevertheless, we have been pleased with the reception of

Chocolate® PTCA Gen 1 and are continuing to build our experience and user base with this unique catheter," stated Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular. "With this rapid approval of Gen 2, we now expect greater ease of use in a broad subset of coronary lesions which we believe will allow us to increase the user base even further."

In addition to Chocolate® PTCA, the Group manufactures a "sister" product, Chocolate® Percutaneous Transluminal Angioplasty (Chocolate® PTA) for the treatment of diseased peripheral vessels. By reducing acute trauma, Chocolate® PTA is able to reduce severe dissections and thus reduce the need for unplanned stenting compared to conventional balloons. [(1)] The Chocolate® PTA also acts as the platform for the Group's novel drug-coated balloon, Chocolate Touch. With the addition of the proven drug, paclitaxel, to the low trauma Chocolate® platform, Chocolate Touch offers the potential to address one of the major limitations of current drug-coated balloons; acute trauma which leads to dissections and unplanned stenting.

[(1)] Dr. Tony Das, et al. "Chocolate® BAR: Chocolate PTA in a broad range of patients with PAD, a prospective post-marketing study", LINC 2014

~~ End ~~

ABOUT QT VASCULAR LTD.

(SGX Stock code: 5I0, Bloomberg Code: QTVC SP, Reuters Code: QTVA.SI)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, based in Pleasanton, California. Its vascular solution products include a range of percutaneous transluminal angioplasty ("**PTA"**) and percutaneous transluminal coronary angioplasty ("**PTCA**") products.

With the exception of its direct sales of its coronary products (Chocolate® PTCA Balloon Catheter and Glider™ PTCA Balloon Catheter) in the United States, these products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group is also applying for CE mark approval with respect to the Chocolate® Touch, its advanced drug-coated peripheral balloon.

For more information, please visit the company website at www.qtvascular.com

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light

of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.